phrykt

Polaryx Therapeutics, Inc. (PLYX): who owns it and who trades it

As of Oct 30, 2026, PLYX insiders reported 2 purchases worth $368K in the last 12 months. The largest buyer was Mstone Partners Healthcare Ltd (Director), with $360K.

Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, PLYX insiders reported $368K of open-market purchases and $0 of sales.

Purchases, 12 months
$368K
2 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
May 27, 2026
Filed May 28, 2026

Purchases and sales by month

$360K$360KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
May 27, 2026Mstone Partners Healthcare Ltd +1DirectorPurchase88,453$4.07$360KForm 4
Feb 18, 2026G. Michael LandisCFOPurchase2,867$2.79$8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Mstone Partners Healthcare LtdDirector, 10% owner$360K–May 27, 2026
G. Michael LandisChief Financial Officer, Director$8K–Feb 18, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PLYX short interest

Low short interest. 0.3% of PLYX shares are sold short: about 1 share in 361. Over the last 12 reports the number of shares short went down 23%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 138,265 PLYX shares were sold short, 0.3% of the shares outstanding, up 16.9% from the report before. At the average daily volume of 21,340 shares, buying them all back would take about 6.5 trading days (days to cover).

Shares short, % of all shares

0.28%May 15Oct 301.04%

Days to cover

6.5May 15Oct 307.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026138,2650.28%+17%21,3406.5
Oct 15, 2026118,3000.24%-17%35,4963.3
Sep 30, 2026143,3390.29%-23%32,1944.5
Sep 15, 2026186,7670.37%-9%29,2066.4
Aug 31, 2026204,4890.41%-18%120,3331.7
Aug 14, 2026249,0380.50%-3%95,9152.6
Jul 31, 2026256,7670.52%-16%103,6102.5
Jul 15, 2026306,5290.65%-25%100,7173.0
Jun 30, 2026408,5160.86%-8%106,9653.8
Jun 15, 2026441,7170.93%+27%215,3102.0
May 29, 2026347,1840.73%+93%592,0851.0
May 15, 2026180,1090.38%-32%163,6941.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Polaryx Therapeutics company events

Polaryx Therapeutics filed 5 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Sep 14, 2026.

  1. Sep 14, 2026VoteReported shareholder vote results. Filing
  2. Sep 1, 2026AnnouncementThe Company appointed Will Charlton, M.D., M.A.S. as its Chief Medical Officer, effective September 1, 2026. Filing
  3. Jul 21, 2026LeadershipLisa Bollinger, MD, Chief Medical Officer of Polaryx Therapeutics, Inc., resigned from her position with the Company, effective immediately. Filing
  4. Jul 17, 2026AnnouncementOf this Current Report on Form 8-K is incorporated by reference into this Item 5.08. Filing
  5. May 28, 2026AgreementPolaryx Therapeutics, Inc. entered into a Securities Purchase Agreement with approximately 35 investors, including existing investors, pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement a total of 2,502,696 shares of the Company’s common stock, par value… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Polaryx Therapeutics financials

Questions about Polaryx Therapeutics, Inc. (PLYX) stock

Are PLYX insiders buying or selling?

In the last 12 months, PLYX insiders reported 2 open-market purchases worth $368K and no sales. The latest trade was on May 27, 2026. See every trade.

What is the short interest in PLYX?

As of Oct 30, 2026, 138,265 PLYX shares were sold short, 0.3% of the shares outstanding, up 16.9% from the report before. At the average daily volume of 21,340 shares, buying them all back would take about 6.5 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.